Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Registry sponsor category
Industry
- Other names
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- Company name
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (8)
- A Study of Picankibart in Patients With Active Psoriatic Arthritis
- A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
- A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
- IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
- Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
- Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors